Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/12/2025 | Outperform | William Blair | |
| 12/3/2025 | $47.00 | Strong Buy | Raymond James |
| 11/7/2025 | $26.00 | Buy | BTIG Research |
| 9/29/2025 | $24.00 | Buy | Stifel |
| 6/30/2025 | $40.00 | Buy | H.C. Wainwright |
| 3/10/2025 | $29.00 | Overweight | Morgan Stanley |
| 3/10/2025 | $22.00 | Buy | BofA Securities |
| 3/10/2025 | $50.00 | Overweight | Cantor Fitzgerald |
Multiple active sites and strong US enrollment continue to support Q3 2026 timing for topline data readout Clinical trial sites in Canada and the United Kingdom have received regulatory clearance to enroll All patients who have completed HERO trial to date have successfully enrolled and remain in the Open Label Extension trial SAN DIEGO, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announced that the first patient has been dosed in Australia in its Phase 3 HERO pivo
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announced that it will present at the following conferences during December: Piper Sandler 37th Annual Healthcare Conference in New YorkPresentation: Wednesday, December 3 at 8:00 a.m. ETEvercore ISI 8th Annual Healthcare Conference in MiamiPresentation: Thursday, December 4 at 11:15 a.m. ET Live webcasts of each presentation will be accessible on the company's website, www.aardvarktherapeutics.com, under the i
Aardvark has aligned with the FDA to reduce the minimum age of eligibility from 13 to 10 years old for pediatric patients in HERO, the Phase 3 trial of ARD-101 for the treatment of hyperphagia associated with Prader-Willi Syndrome (PWS) New preclinical data presented at ObesityWeek 2025 demonstrates the potential of ARD-201 in enhanced glucose control, along with preservation of lean body mass, underscoring its opportunity in addressing key challenges in today's obesity treatment landscape Oral ARD-201 shows potential for weight management after GLP-1RA discontinuation, supported by new promising preclinical results and ARD-101 clinical data $126.4 million in cash, cash equivalents, and
8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)
10-Q - Aardvark Therapeutics, Inc. (0001774857) (Filer)
8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)
4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
William Blair initiated coverage of Aardvark Therapeutics with a rating of Outperform
Raymond James initiated coverage of Aardvark Therapeutics with a rating of Strong Buy and set a new price target of $47.00
BTIG Research initiated coverage of Aardvark Therapeutics with a rating of Buy and set a new price target of $26.00
SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that members of its team will join the Prader-Willi syndrome (PWS) community at the 2025 United in Hope Conference, taking place June 24 to 28 in Phoenix, Arizona. "It's an honor to stand alongside the families, advocates, scientists and clinicians who are working to transform the lives of those affected by PWS," said Dr. Tien Lee, Chief Executive Officer of Aardvark Therapeutics. "The United in